Triple antiviral therapy in HCV positive patients who failed prior combination therapy

Table 3 Sustained virologic response in patients treated with Peg IFN or standard IFN according to the baseline characteristics of patients

Characteristic	PegIFN+RBV+AMA		IFN+RBV+AMA		P
Genotype 1	21/82	26%	11/65	17%	NS
Non 1	13/24	54%	5/17	29%	NS
Age ≤ 40 yr	11/23	48%	2/19	11%	0.017
> 40 yr	23/83	28%	14/63	22%	NS
BMI ≤ 25 kg/m2	22/60	37%	10/47	21%	NS
> 25 kg/m2	8/33	24%	4/28	14%	NS
Stage ≤ 3	27/71	38%	10/56	18%	0.018
> 3	6/30	20%	6/26	23%	NS
Grade ≤ 10	28/94	30%	14/73	19%	NS
> 10	6/9	67%	2/6	33%	NS
ALT ≤ 120 UI/L	17/64	27%	5/43	12%	NS
> 120 UI/L	15/35	43%	9/31	29%	NS
HCV-RNA ≤ 2 × 106 copies/mL	15/41	37%	8/33	24%	NS
> 2 × 106 copies/mL	6/13	46%	1/15	7%	0.029

NS: Not significant.